ArticleBritish journal of cancer2023

Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study.

Linbin Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.